Researchers untangle the APOE4 gene, the most significant genetic risk factor for Alzheimer's disease

Findings may lead to new strategies, drugs to combat the condition

Date:: June 23, 2022
Source:: Boston University School of Medicine
Summary:: Researchers have discovered two important novel aspects of the gene: 1) human genetic background inherited with APOE4 is unique to APOE4 patients and 2) the mechanistic defects due to APOE4 are unique to human cells.
Share:: Facebook Twitter Pinterest LinkedIN Email

FULL STORY

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, affecting more than 5.8 million individuals in the U.S. Scientists have discovered some genetic variants that increase the risk for developing Alzheimer's; the most well-known of these for people over the age of 65 is theAPOEε4 allele. Although the association betweenAPOE4and increased AD risk is well-established, the mechanisms responsible for the underlying risk in human brain cell types has been unclear until now.

Researchers from Boston University School of Medicine (BUSM) have discovered two important novel aspects of the gene:

1) human genetic background inherited withAPOE4is unique toAPOE4patients and

2) the mechanistic defects due toAPOE4are unique to human cells.

"Our study demonstrated what theAPOE4gene does and which brain cells get affected the most in humans by comparing human and mouse models. These are important findings as we can find therapeutics if we understand how and where this risk gene is destroying our brain," says corresponding author Julia TCW, PhD, assistant professor of pharmacology & experimental therapeutics at BUSM.

To investigate the effects ofAPOE4on brain cell types, the researchers used three models, human induced pluripotent stem cells (hiPSCs), post-mortem human brains and experimental models. They used a population hiPSC model, comparingAPOE4(mutation) vs.APOE3(mutation-free) of AD patients and normal people. For the second model, they compared AD brains against a control brain with differentAPOEgenotypes. For the third model, they used an experimental model carrying humanAPOEgenes. With all, they used genetic screening and RNA sequencing to identify human cell-type specific defects due toAPOE4.

"Our study supports that the genetic background aroundAPOEregion can modify theAPOE4risk effects. Therefore, apart from finding drugs to reduce theAPOE4risk, modulating targets to mimic brains carrying protective genes or genetic backgrounds can be another strategy to reduce the risk of developing AD," adds TCW.

While this study is aboutAPOE4gene using Alzheimer's patient samples, it is also known thatAPOE4is risk for Parkinson's disease (PD). According to TCW, this study has implications for any disease associated withAPOEas risk such as AD and PD, or for any disease phenotype found similar to the one caused byAPOE4, such as rare genetic diseases.

These findings appear online in the journalCell.